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Abstract 19 
Antibiotic resistance is mediated through several distinct mechanisms, most of which are relatively 20 
well-understood and the clinical importance of which has long been recognised. Until very recently, 21 
neither of these statements was readily applicable to the class of resistance mechanism known as 22 
target protection, a phenomenon whereby a resistance protein physically associates with an antibiotic 23 
target to rescue it from antibiotic-mediated inhibition. In this Review, we summarize recent progress 24 
in understanding the mechanisms involved in target protection and its clinical importance. In 25 
particular, we describe the current state of knowledge regarding the molecular basis of the known TP 26 
systems, emphasizing the fact that TP does not involve a single, uniform mechanism – but is brought 27 
about in several, mechanistically-distinct ways.  28 
[H1] Introduction 29 
Bacteria have evolved an array of mechanisms that enables them to resist the inhibitory action of 30 
antibiotics, a phenomenon that is eroding our ability to manage bacterial infections1. Understanding 31 
the molecular details of these resistance mechanisms is not only of fundamental interest, but can also 32 
offer strategic intelligence to inform the rational development of novel therapeutic approaches to 33 
evade or block resistance. As befits a mature field of study, the beginnings of which predate the clinical 34 
deployment of penicillin2, by now there exists an extensive body of knowledge regarding the nature of 35 
different mechanistic classes of antibiotic resistance, including drug efflux and degradataion as well as 36 
target modification and mutation3,4. One class of resistance mechanism that has long lagged behind 37 
the others — both in terms of perceived clinical impact and mechanistic understanding — is a 38 
phenomenon known as target protection.  39 
 40 
Target protection involves the physical association of a resistance protein (‘target protection protein’) 41 
with an antibiotic target to rescue the function of the latter from antibiotic-mediated inhibition. In 42 
contrast to the more familiar mechanism of target modification, whereby the interaction between the 43 
resistance protein and the target need in principle occur only once and results in chemical alteration 44 
of the latter, target protection does not involve permanent modification of the target. Instead, direct 45 
interaction between the target protection protein and the target is required to effect resistance4. 46 
Target protection was first recognized as a mechanism of antibiotic resistance in the context of 47 
tetracycline resistance ~30 years ago5,6, and for some considerable time thereafter this remained the 48 
only clearly documented example. Consequently, target protection has generally been considered little 49 
more than an unusual foot-note alongside the better-known mechanisms by which bacteria resist 50 
antibiotics. Certainly, it was believed to have limited impact in terms of mediating clinically significant 51 
resistance to antibiotics, and literature descriptions of antibiotic resistance mechanisms often fail to 52 
mention it and/or fail to distinguish it from target modification. 53 
 54 
However, recent work has now revealed that target protection is a key mechanistic player in clinically 55 
significant antibiotic resistance that affects diverse classes of antibacterial drugs and is prevalent in 56 
bacterial pathogens. Furthermore, whereas the target protection mechanism of tetracycline resistance 57 
involves direct displacement of the drug from the target (see below), structural and functional 58 
characterization of other target protection systems has revealed modes of protection that are 59 
mechanistically distinct from this canonical example. In fact, target protection can be divided into three 60 
distinct types with respect to the underlying protection mechanism (Fig. 1): by sterically removing the 61 
drug from the target; by inducing conformational changes within the target that allosterically dissociate 62 
the drug from the target, or by inducing conformational changes within the target that restore 63 
functionality despite the presence of the bound antibiotic. In this Review, we examine the major recent 64 
developments that have improved our understanding of the nature and importance of this mechanistic 65 
class, with the emphasis on the molecular detail of their action. 66 
 67 
[H1] Tetracycline ribosomal protection proteins  68 
Members of the tetracycline class of antibiotics inhibit bacterial translation by binding to the 30S 69 
ribosomal subunit and interfering with delivery of the incoming aminoacyl-tRNA by elongation factor 70 
Tu (EF-Tu) during the elongation phase of protein synthesis7. Tetracyclines achieve this by binding to 71 
helix 34 of the 16S rRNA at a position that overlaps with the anticodon loop of the aminoacyl-tRNA 72 
when accommodated at the A-site of the decoding centre8-11. Bacterial resistance to this class can 73 
result through diverse mechanisms, although two mechanistic types predominate as a cause of 74 
clinically significant resistance in pathogens: active efflux of the antibiotic and target protection. 75 
Tetracycline ribosomal protection proteins (TRPPs) mediate target protection, and 13 distinct TRPP 76 
classes have been described to date12 of which Tet(O) and Tet(M) are the best-characterized7,13. Genes 77 
encoding TRPPs are found in a diverse range of Gram-negative and Gram-positive pathogens14. TRPPs 78 
represent the major cause of tetracycline resistance in Gram-positive pathogens, and tet(M) is by far 79 
the most prevalent tetracycline resistance determinant in clinical isolates of streptococci15,16, 80 
staphylococci17,18 and enterococci19,20. 81 
 82 
Tet(M) and Tet(O) are closely related GTPases with sequence homology (25% identity) to translation 83 
elongation factor-G (EF-G), and thus seem to represent EF-G paralogs that have evolved the specialized 84 
ability to rescue translation in the presence of tetracyclines7. Indeed, structural studies have shown 85 
that Tet(O) and Tet(M) bind to the ribosome in manner analogous to EF-G21-24. However, whereas EF-86 
G recognises the ribosome in a pre-translocational state (that is, the A-site and P-site are occupied by 87 
tRNAs), Tet(O) and Tet(M) bind to a post-translocational state (that is, the P-site and E-site are 88 
occupied, with the A-site being free owing to the presence of tetracycline)21-24. The first, low-resolution 89 
(16 Å), cryo-electron microscopy structure of Tet(O) bound to the ribosome led to the suggestion that 90 
this TRPP indirectly drives the removal of tetracycline from the target by inducing a local disturbance 91 
in helix 34 (Ref. 21) However, subsequent higher-resolution (3.9 Å to 9.6 Å) structures have established 92 
that both Tet(O) and Tet(M) directly overlap the tetracycline binding site on the ribosome22-24 (Fig. 2), 93 
thereby mediating resistance through direct physical displacement of the drug. In all of these structural 94 
studies, the TRPP was trapped on the ribosome using non-hydrolysable GTP analogs, consistent with 95 
earlier biochemical studies indicating that GTP hydrolysis is required for factor dissociation rather than 96 
drug release25,26. The most recent and best-resolved structure revealed that a conserved proline 97 
residue located at the tip of loop III of domain IV of Tet(M) is located directly within the tetracycline-98 
binding site where it interacts with nucleotide C1054 of the 16S rRNA24 (Fig. 2). Based on changes in 99 
chemical reactivity to RNA-modifying agents it has been proposed that TRPPs alter the conformation 100 
of nucleotides within the drug-binding site (for example, C1054), which disfavors immediate rebinding 101 
of the drug as well as promoting subsequent delivery of the aa-tRNA by EF-Tu7,13. As the conformation 102 
of C1054 seems identical between the available Tet(M)-bound and tetracycline-bound 70S ribosome 103 
structures10,24, any such alterations within the drug-binding site must occur upon dissociation of the 104 
TRPP from the ribosome. Thus, conformational changes within the TRPP that are associated with GTP 105 
hydrolysis may not only facilitate dissociation from the ribosome but could induce conformational 106 
change within the drug-binding site that persists following TRPP dissociation.  107 
 108 
Although TRPPs mediate resistance to classic tetracyclines, they have little or no effect on the activity 109 
of third-generation compounds, such as tigecycline and omadacycline10,27,28. The ability of these drugs 110 
to overcome the action of Tet(M) is not solely attributable to their increased affinity of ribosome 111 
binding relative to tetracycline, as the activity of other tetracycline analogs (for example, azacycline) 112 
that exhibit comparable affinity is also impaired by Tet(M)10. Potentially, the C9-moiety of the third 113 
generation tetracyclines that enhances ribosome binding also sterically hinders access of residues 114 
within loop III of domain IV of Tet(M) to nucleotide C1054, thereby preventing the TRPP from dislodging 115 
the drug from its binding site (Fig. 2). In line with this idea, Tet(M) variants selected through laboratory 116 
evolution to mediate tigecycline resistance carry substitutions within this very loop29. 117 
 118 
Target protection involving direct physical displacement of the drug from its target by the protection 119 
protein, exemplified by the TRPPs, can be referred to as type I target protection (Fig. 1). 120 
 121 
[H1] Antibiotic resistance ABC-F proteins. 122 
In 2016, antibiotic resistance (ARE) ABC-F proteins have been shown to bind the bacterial ribosome to 123 
protect it from translation inhibitors, which has further strengthened the notion that target protection 124 
is a mechanism of clinically significant resistance30. The long-standing controversy surrounding the 125 
mechanism of resistance of these proteins, and their importance in resistance to a broad range of 126 
clinically deployed antibiotics against Gram-positive pathogens, have recently been reviewed31 and will 127 
not be revisited here. This group of proteins constitutes a major source of clinical resistance to almost 128 
all antibacterial drug classes that target the 50S subunit of the ribosome (lincosamides, macrolides, 129 
oxazolidinones, phenicols, pleuromutilins and streptogramins of groups A and B), and collectively 130 
mediates resistance to a broader range of structurally distinct antibiotic classes than any other family 131 
of resistance factors. 132 
 133 
ABC-F proteins lack the transmembrane portions found in most other members of the ATP-binding 134 
cassette (ABC) superfamily, and instead comprise two ABC domains that are separated by a linker 135 
region30-32. This linker has been designated the P-site tRNA-interaction motif (PtIM)33,34, although 136 
amongst the ARE ABC-F proteins, it is also referred to as the antibiotic resistance domain (ARD)35. Three 137 
major categories of ARE ABC-F proteins can be differentiated on the basis of their antibiotic specificity:  138 
Vga, Lsa, Sal and Vml belong to the first category, and they mediate resistance to streptogramins of 139 
group A, lincosamides and sometimes pleuromutilins;  Msr-type proteins mediate resistance to 140 
streptogramins of group B and macrolide antibiotics (and sometimes ketolides);  and  Optr and Poxt 141 
mediate resistance to oxazolidinones and phenicols31,32,36-38. Structures of representatives from the 142 
first two groups (VmlR from Bacillus subtilis and MsrE from Pseudomonas aeruginosa) in complex with 143 
the ribosome have revealed that these proteins bind into the E-site, with their ARDs reaching into the 144 
peptidyltransferase centre (PTC) 35,39,40 (Fig. 3). To access the PTC, these proteins induce a 145 
conformational change within the P-site tRNA, shifting the acceptor arm out of the PTC and towards 146 
the ribosomal A-site35,39. The loop located at the tip of the ARD varies considerably in length and 147 
sequence between ARE ABC-F proteins, and mutations within this region can affect antibiotic 148 
specificity31,35,39,41,42. When bound to the ribosome, a residue (Phe237) within the ARD loop of VmlR 149 
sterically overlaps the binding site of PTC-inhibiting antibiotics, such as lincosamides, streptogramins 150 
of group A and pleuromutilins 35, consistent with the reported resistance spectrum of this protein (Fig. 151 
3)35,43. However, an engineered VmlR variant in which Phe237 was replaced with Ala — a substitution 152 
that would be predicted to remove the overlap — still conferred resistance to lincosamides and 153 
pleuromutilins 35, which suggests that the steric overlap is not critical for VlmR-mediated removal of 154 
these antibiotics from the ribosome. By contrast, this same VlmR variant lost the ability to mediate 155 
resistance to virginiamycin M35, which implies that an important steric component exists for removal 156 
of streptogramins of group A. In the case of MsrE, the ARD loop is longer and reaches deeper into the 157 
ribosomal exit tunnel, where Leu242 of MsrE overlaps with the binding site of macrolides and 158 
streptogramins of group B 39 (Fig. 3). Substitution of Leu242 to Ala leads to near-complete loss of ability 159 
to mediate azithromycin resistance, which suggests a strong steric component to the mechanism of 160 
macrolide removal from the ribosome39. Whether MsrE functions sterically or allosterically on 161 
streptogramins of group B remains to be determined. Taken together, these observations imply that 162 
the precise nature of the target protection mechanism of ARE ABC-F proteins depends not only on the 163 
target protection protein itself, but can also vary amongst the targeted antibiotic class. Thus, in some 164 
cases (for example, MsrE-mediated macrolide resistance) ARE ABC-F proteins seem to function via a 165 
type I target protection mechanism through direct physical displacement of the antibiotic from the 166 
target, analogous to that seen for the TRRPs. In other cases (for example, VmlR-mediated resistance to 167 
lincosamides and pleuromutilins) resistance is the result of an indirect, allosteric mechanism of 168 
antibiotic removal — termed type II target protection (Fig. 1). 169 
 170 
ATP hydrolysis by the ARE ABC-F proteins does not seem to be required for antibiotic release, but it is 171 
required for dissociation of the resistance protein from the ribosome35,37,39. Following dissociation, the 172 
allosteric changes induced in the ribosome by the ABC-F protein may persist to prevent immediate 173 
rebinding of the drug, as seen for the TRPPs. Nevertheless, any such induced conformational change is 174 
unlikely to be retained throughout the process of accommodating the next incoming aminoacyl-tRNA 175 
and the subsequent translocation step, which could mean that the ABC-F proteins must rebind the 176 
ribosome after each translation elongation cycle to ensure effective target protection in the presence 177 
of the antibiotic31,44. However, this is not necessarily the case. For the Msr proteins that mediate 178 
resistance to macrolides, one could envisage a situation in which re-accommodation of short peptidyl-179 
tRNA into the exit tunnel would enable continued translation that, in turn, could mask the macrolide-180 
binding site and thereby prevent drug rebinding. Likewise, for proteins such as Vga, Lsa, Sal or Vml that 181 
mediate resistance to translation initiation inhibitors (for example, streptogramins of group A, 182 
lincosamides and pleuromutilins), re-accommodation of initiator fMet-tRNA at the PTC would enable 183 
peptide bond formation with the incoming aminoacyl-tRNA to create an elongation complex that is 184 
refractory to the action of these antibiotics. However, these ideas require experimental corroboration. 185 
 186 
The molecular basis for the antibiotic specificity of ARE ABC-F proteins will also require further study. 187 
For example, VmlR mediates resistance to streptogramins of group A, lincosamides and pleuromutilins, 188 
but not to oxazolidinones and phenicols, even though all of these classes have binding sites at the PTC 189 
that overlap with each other and with the ARD of VmlR35. Similarly, MsrE mediates resistance to 190 
streptogramins of group B and macrolide antibiotics, but not streptogramins of group A, lincosamides, 191 
pleuromutilins, oxazolidinones and phenicols, despite the overlap in binding site of these classes39. A 192 
potential explanation for this specificity could relate to the functional state of the ribosome that 193 
becomes trapped by these antibiotic classes; whereas streptogramins of group A, lincosamides, 194 
pleuromutilins interfere with translation initiation45-49, oxazolidinones and phenicols predominantly 195 
target elongation50. Thus, the majority of ribosomes stalled by oxazolidinones and phenicols would 196 
contain P-site tRNA attached to a long nascent polypeptide chain, a structure that is conceivably 197 
refractory to VmlR and MsrE binding and action. By contrast, ribosomes stalled by streptogramins of 198 
group A, lincosamides, pleuromutilins during initiation would have an fMet-tRNAiMet trying to 199 
accommodate at the P-site, and thereby represent an appropriate substrate for VmlR action. In this 200 
regard, the C-terminal extension (CTE) of VmlR may have a role in recognition of the initiation state, as 201 
the CTE reaches into the cavity on the 30S subunit where the Shine-Dalgarno-helix is located35. Indeed, 202 
the CTE is critical for resistance in VmlR35 and is conserved in Vga-type proteins. However, potentially 203 
arguing against a specific role for the CTE during initiation is the fact that this region is absent in Lsa-204 
type ARE ABC-F proteins that have the same antibiotic specificity as Vga and Vml proteins, but are 205 
present in OptrA, which mediates resistance to oxazolidinones and phenicols that stall ribosomes 206 
during elongation32,37. Lastly, it will also be interesting to understand how Optr and Poxt proteins 207 
manage to dislodge oxazolidinones and phenicols from the ribosome, as these proteins have a very 208 
short ARD that would not be expected to reach into the PTC32. 209 
 210 
[H1] FusB-type proteins 211 
The antibiotic fusidic acid inhibits bacterial protein synthesis by binding to translation elongation factor 212 
EF-G on the ribosome and preventing disassembly of the post-translocation complex; the resultant 213 
steric occlusion of the A-site by EF-G blocks the delivery of incoming aminoacyl-tRNA species into the 214 
ribosome, causing cessation of protein synthesis51-53. Resistance to fusidic acid amongst clinical isolates 215 
of Staphylococcus aureus and other staphylococci has increased dramatically in recent years, and 216 
predominantly results from horizontal acquisition of determinants encoding FusB-type proteins54-58. 217 
This family, the best studied of which is FusB itself, comprises small (~25 kDa), two-domain 218 
metalloproteins that bind to the C-terminal domains of EF-G and rescue translation in the presence of 219 
the drug 59-61 (Fig. 4a). In contrast to the target protection mechanisms described above, these fusidic 220 
acid resistance proteins do not bind the target in close proximity to the drug; FusB recognises a region 221 
in EF-G that is entirely distinct from the fusidic acid-binding site, and indeed involves different domains 222 
of the protein (FusB makes contacts with domain IV and domain V of EF-G, whereas fusidic acid binds 223 
at a site located between domain II and domain III) 62,63 (Fig. 4b,c). FusB-type resistance does therefore 224 
not result from direct physical displacement of the antibiotic from the drug target, nor is there evidence 225 
to implicate an allosteric mechanism of drug removal. Instead, resistance is attributed to the ability of 226 
FusB-type proteins to modulate EF-G function in a manner that overcomes fusidic acid-mediated 227 
inhibition. In biochemical assays monitoring dissociation of EF-GGDPribosome complexes, FusB 228 
mediates a dose-dependent increase in the rate at which EF-G leaves the ribosome, an effect that is 229 
observed even in the absence of fusidic acid60. By driving disassembly of the post-translocation 230 
complex, FusB effectively counters the opposing action of fusidic acid, thereby mitigating the inhibitory 231 
effect of the drug60 (Fig. 4a).  232 
 233 
Although a comprehensive description of the target protection mechanism of FusB-type proteins 234 
awaits additional molecular elucidation, our current understanding supports the following model. 235 
Substantial conformational rearrangement within EF-G is required to enable its dissociation from the 236 
post-translocation complex64. This rearrangement is driven by GTP hydrolysis within the N-terminal 237 
super-domain of the protein (domain I and domain II), with subsequent transmission to the C-terminal 238 
super-domain (domain III to domain V) to disrupt the contacts that domain IV makes with the 30S 239 
subunit64,65. By binding into a region that spans domain II and domain III, fusidic acid effectively tethers 240 
the two super-domains together and restricts this relay of conformational change, thereby inhibiting 241 
EF-G release63. Binding of FusB to EF-G has been shown to induce conformational change within 242 
domain IV and domain V and altered dynamics in domain III, changes that alone or together presumably 243 
drive EF-G dissociation from the ribosome62. By inducing these changes directly within the C-terminal 244 
super-domain of EF-G, the usual requirement for transmission of conformational change from the N 245 
terminus is lifted, thereby effectively nullifying the inhibitory action of fusidic acid. Although this target 246 
protection mechanism does not require or result from removal of the drug from the target, fusidic acid 247 
is likely to dissociate from EF-G once the latter has been dislodged from the ribosome, as it has only 248 
low affinity for free (non-ribosome bound) EF-G. 249 
 250 
Thus, the third mechanistic type of target protection (type III target protection mechanism)  does not 251 
involve protection of the target by reversal of antibiotic binding, but instead restores functioning of 252 
the target even with the antibiotic bound (Fig. 1).  253 
 254 
[H1] Other examples of target protection. 255 
The three target protection systems described above all have in common that there has been 256 
considerable recent progress in understanding the molecular mechanism underlying protection, which 257 
enables us to classify them into distinct types of target protection, and they are clinically significant 258 
causes of antibiotic resistance. The following paragraphs examine other antibiotic resistance proteins 259 
that, although failing to fulfil one or both of these criteria, nonetheless represent (or are likely to 260 
represent) examples of target protection, and further studies will provide important insights into the 261 
underlying mechanisms. 262 
 263 
[H2] Target protection mediated by the quinolone resistance proteins. The quinolone resistance (Qnr) 264 
family of pentapeptide repeat proteins mediates reduced susceptibility to quinolones and 265 
fluoroquinolones in Gram-negative pathogens, such as the Enterobacteriaceae, by binding and 266 
protecting the cellular targets (type II topoisomerases) from drug action66-68. Although the degree of 267 
protection provided by Qnr proteins is insufficient to render the bacteria that harbour them resistant 268 
according to clinical breakpoints, the qnr determinants are nonetheless of considerable importance 269 
because their presence both reduces the efficacy of fluoroquinolone treatment and facilitates the 270 
selection of higher-level (‘true’) fluoroquinolone resistance69. Qnr proteins adopt a right-handed β-271 
helical fold that broadly mimics B-form DNA70,71, a structure that could potentially enable them to bind 272 
into the central DNA-binding groove of type II topoisomerase enzymes71. Binding of Qnr to these 273 
enzymes is proposed to destabilize the complex that the drug forms with topoisomerase-bound 274 
cleavage sites on DNA, thereby enabling re-ligation of DNA and regeneration of the active enzyme69-71. 275 
It remains to be understood in detail how this protective effect is mediated, including whether Qnr-276 
type proteins primarily drive the dissociation of the drug — either directly or indirectly (type I or type 277 
II target protection, respectively) — or whether they restore topoisomerase function despite the 278 
presence of the bound drug (type III target protection).  279 
 280 
[H2] Target protection mediated by cis-acting peptides. It has long been known that certain short 281 
peptides can protect the ribosome translating them from the action of the related macrolide and 282 
ketolide antibiotic classes (reviewed in Ref. 72). To explain this, a ’bottle-brush’ model has been 283 
proposed73 that effectively describes a type I target protection mechanism; the short peptide, as it is 284 
being translated, interacts with the antibiotic within the ribosomal tunnel, eventually dislodging it as 285 
the peptide is released from the P-tRNA during termination74. However, the biological relevance of this 286 
remains unclear. The majority of E-peptide and K-peptide sequences (named to indicate their ability to 287 
mediate resistance to erythromycin (representative macrolide) or ketolides, respectively) that have 288 
been studied derive from random peptide libraries73,75,76. Furthermore, although the original E-peptide 289 
(MRMLT) is encoded within the 23S rRNA of Escherichia coli77, there is no evidence that it is expresses 290 
in native settings72. A recent study identified a novel 61 amino-acid long polyproline-containing peptide 291 
from a soil metagenome that shares sequence similarity with these short resistance peptides, and 292 
which when overexpressed in E. coli also confers resistance to macrolides and ketolides78. Specifically, 293 
the N-terminal sequence (MSWKL) of the  peptide is reminiscent of E-peptides (MSLKV, MFSKL, 294 
MNWKL)75 and K-peptides (MSWKI)73, raising the possibility that it also confers resistance in cis by 295 
dislodging macrolides and ketolides from the ribosome as the peptide is being translated78. Although 296 
a compelling idea, it will need to be reconciled with the observation that ‘classic’ E-peptides are 297 
typically only functional in their short form, and extending them by removal of the stop codon or 298 
appending the E-peptide sequence to the C-terminus of a polypeptide abrogates their ability to confer 299 
resistance77. Further investigation will also be required to understand whether the central region of 300 
the 61 amino-acid long peptide, which is extremely proline rich (25 proline residues within ten PPx 301 
motifs), has any role in drug displacement and antibiotic resistance. 302 
 303 
[H2] Target protection mediated by HflX-type proteins. Treatment of Listeria monocytogenes with sub-304 
inhibitory concentrations of lincosamides dramatically affects the gene expression program, including 305 
inducing transcription of Lmo0919 (an ARE ABC-F protein)47 and Lmo076279. The latter has been found 306 
to mediate modest levels of resistance to lincosamides and macrolides, an effect that is only apparent 307 
in a genetic background lacking Lmo091979. Lmo0762 exhibits homology to HflX79, a ribosome-splitting 308 
GTPase that rescues stalled ribosomes under stress conditions80,81. Reflecting this similarity and the 309 
fact that the protein mediates a degree of antibiotic resistance, it was subsequently termed HflXr, a 310 
descriptor that also distinguishes it from another listerial HflX protein (Lmo1296) that has no role in 311 
resistance79. Analogous to HflX, HflXr seems to induce dissociation of 70S ribosomes into their 30S and 312 
50S subunits. However, it remains unclear whether HflXr is also directly responsible for antibiotic 313 
displacement or whether another factor is recruited to the antibiotic-bound 50S particles to fulfil this 314 
function79. We note that in the cryo-electron microscopy structure of the E. coli HflXGDPNP50S 315 
complex, the loop connecting two helices of subdomain II within the N-terminal domain of HflX is 316 
positioned at the PTC in close proximity to the lincosamide-binding site (Fig. 5a); as the HflXr loop is 317 
two residues longer than HflX and differs in sequence (Fig. 5b), this offers the possibility that a distinct 318 
conformation adopted by HflXr could reach towards the macrolide-binding site to mediate antibiotic 319 
displacement using a type I or type II target protection mechanism. Independently evolved insertions 320 
within the loop region have also arisen in the HflX proteins of some organisms that lack an HflXr protein, 321 
including Streptomyces fradiae and Mycobacterium abscessus (Fig. 5b), and it has recently been 322 
established that mycobacterial HflX proteins also mediate resistance to macrolides and lincosamides82. 323 
It would be interesting to examine whether HflX and HflXr proteins are associated with resistance to 324 
other PTC-binding antibiotics, such as pleuromutilins, oxazolidinones and streptogramins, which have 325 
overlapping binding sites with macrolides and lincosamides (Fig. 5a). 326 
 327 
[H2] Target protection mediated by antimicrobial peptide ‘transporters’. Until very recently, all 328 
confirmed or apparent examples of target protection occurred inside bacterial cells. A study 83 has now 329 
provided evidence that the BceAB system of Bacillus subtilis mediates target protection at the outer 330 
surface of the cytoplasmic membrane to resist bacitracin and other peptide antibiotics that inhibit cell-331 
wall biogenesis through binding of lipid II cycle intermediates. The following model has been proposed 332 
to describe this target protection mechanism. BceAB spans the cytoplasmic membrane, with its 333 
extracellular portion presented at the cell surface where it can recognise complexes of the antibiotic 334 
bound to the target (undecaprenyl pyrophosphate in the specific case of bacitracin). Subsequent ATP 335 
hydrolysis by the intracellular ATPase domains of BceAB provides the energy to catalyse splitting of 336 
these extracellular antibiotic-target complexes, a process that may constitute a type I target protection 337 
mechanism.  338 
 339 
This model provides a compelling explanation for the long-standing conundrum as to how a protein 340 
complex that resembles a transporter can mediate resistance to an antibiotic that acts on the outer 341 
surface of the bacterium. It also describes a target protection mechanism that is potentially responsible 342 
for resistance to various antibacterial compounds acting outside the cell, and across a range of bacteria 343 
that includes important pathogens. For example, it seems a reasonable assumption that other BceAB-344 
type systems (for example,  the VraDE system in Staphylococcus  aureus84) mediate resistance through 345 
this same mechanism. VraDE makes a substantial contribution to intrinsic resistance to clinically 346 
deployed antibiotics, including daptomycin and bacitracin85, and upregulation of expression of this 347 
peptide detoxification module constitutes a key route by which staphylococci can evolve resistance to 348 
antimicrobial peptides such as nisin86,87. A considerable number of other transporter-like systems are 349 
known to mediate resistance to antimicrobial peptides in bacteria88, and future work should seek to 350 
distinguish those truly functioning as transporters from those mediating resistance via target 351 
protection. 352 
 353 
[H1] The origin of target protection mechanisms 354 
Although some target proteins (for example, the TRPPs) have conceivably evolved as dedicated 355 
antibiotic resistance factors, in other cases resistance is likely to be coincidental to their native cellular 356 
role or roles. For example, the ARE ABC-F and FusB-type proteins seem to be accessory translation 357 
factors that have evolved to optimise functioning of the core protein synthesis machinery31,32,59,60, but 358 
in modulating the conformational and functional properties of this machinery, resistance to antibiotics 359 
results as a by-product. Reinforcing the idea that the original raison d’etre for these proteins is probably 360 
not to provide resistance, they are encoded within the core genomes of organisms that are highly 361 
unlikely to encounter the corresponding antibiotics in their natural habitats59,89. 362 
 363 
The target protection proteins with the clearest evolutionary origins are the enzymatic factors that 364 
protect the ribosome (ARE ABC-Fs, HflXr and TRPPs). In all cases, these have evolved from duplication 365 
of a housekeeping factor; HflX in the case of HflXr, an EF-G-like or EF2-like elongation factor in the case 366 
of TRPPs (Fig. 6), and in the case of ARE ABC-Fs, translation factors of unknown function, but probably 367 
with a role involving PTC modulation for optimisation of translation, perhaps similar to ABC-F EttA32-34 368 
(Fig. 6). Although ARE ABC-Fs and TRPPs have evolved by the same process of duplication, their 369 
phylogenetic trees look very different (Fig. 6). The TRPPs form one very distinct branch in the EF2 370 
family, which indicates that they have a single point of origin that is likely to be extremely ancient (Fig. 371 
6a). By contrast, known ARE ABC-Fs do not branch together, have probably evolved multiple times 372 
independently, and functional diversification into dedicated translation and resistance factors is likely 373 
to be an ongoing process (Fig. 6b).  374 
 375 
As with the ABC-Fs, target protection proteins in the HflX family may constitute a mix of dedicated 376 
resistance factors (HflXr) and multifunctional translation and/or resistance factors. Phylogenetic 377 
analysis indicates that the hflX gene duplication is present in many firmicutes, such as Bacillus cereus 378 
and Clostridium difficile, but is also observed in other phyla, including alpha-, beta-, gamma- and 379 
deltaproteobacteria79, which suggests that HflXr proteins capable of mediating antibiotic resistance 380 
may exist in many different bacterial species. As indicated above, HflX itself seems to be involved in 381 
resistance in some bacteria. Beyond the very recent demonstration that mycobacterial HflX mediates 382 
macrolide resistance82, the S. fradiae hflX gene resides within the biosynthetic gene cluster of the 383 
macrolide, spiramycin90, and functional metagenomic databases constructed from antibiotic-rich 384 
environments have identified hflX genes as putative resistance determinants in Simkania negevensis 385 
and Emergencia timonensis78,91. 386 
 387 
Evolutionary parallels can be drawn between target protection and target modification mechanisms of 388 
antibiotic resistance, with examples again coming from the ribosome. The Cfr and Erm resistance 389 
proteins evolved from the housekeeping rRNA methyltransferases RlmN and KsgA, respectively92-94. 390 
Thus, in addition to carrying out their primary roles, proteins that work with the core cellular machinery 391 
are an important reservoir from which resistance could evolve by virtue of their innate ability to 392 
interact with or functionally modulate the target of the antibiotic. As a consequence, and as with target 393 
protection mechanisms, the boundary is blurred between what is a housekeeping or resistance factor. 394 
The fact that target protection can be ‘accidental’ helps to explain the existence of mechanisms against 395 
wholly synthetic antibacterial agents unlike those that exist in nature (for example,  OptrA and PoxtA 396 
as a mechanism of resistance to the oxazolidinones), and highlights the scope for resistance to future 397 
antibacterial drugs (including synthetic agents) to emerge through target protection.  398 
 399 
[H1] Overcoming target protection.   400 
A growing appreciation of the molecular detail of target protection could help to inform the rational 401 
development of therapeutic approaches for overcoming this class of resistance mechanism. There are 402 
two basic strategies for mitigating resistance to a given antibacterial drug class, both of which have 403 
been successfully used clinically to restore the therapeutic utility of agents whose activity has become 404 
compromised by resistance. The first of these involves generating analogues of the drug scaffold, with 405 
a view to ‘designing-out’ the resistance liability; such an approach has breathed new life into multiple 406 
antibiotic classes that include the β-lactams and the tetracyclines. The second pairs the antibacterial 407 
drug in question with a small-molecule inhibitor of the resistance mechanism, an approach uniquely 408 
exemplified clinically by the use of β-lactamase inhibitors (for example, clavulanic acid) that spare β-409 
lactams from hydrolytic destruction. 410 
 411 
Proof-of-principle already exists that type I target protection can be overcome via the former approach; 412 
as described above, the C9-moiety of the third generation tetracyclines enables them to evade TRPP-413 
mediated resistance. Whether type II or type III target protection can be similarly addressed by 414 
chemical modification of drug classes subject to these resistance mechanisms is unclear. As both types 415 
of target protection effectively proceed via an allosteric mechanism, chemical modification of an 416 
inhibitor to comprehensively evade resistance would probably need to fundamentally alter the nature 417 
of its interaction with the target, something drug analogues do not routinely achieve. Nevertheless, 418 
modification of an antibacterial drug scaffold to increase affinity and/or potency at the level of the 419 
target has been demonstrated to deliver some degree of improvement in antibacterial activity against 420 
bacteria expressing a type II target protection mechanism. Tedizolid, a newer-generation 421 
oxazolidinones, exhibits greater potency than the parent compound of the class (linezolid) against 422 
purified ribosomes in an in vitro translation assay, probably because the drug makes additional 423 
interactions with the 23S rRNA95. This effect on potency is associated with a 4-8 fold increase in 424 
antibacterial activity95, an improvement that is retained against bacteria carrying the ARE ABC-F 425 
protein, OptrA36. This example implies that if an analogue can achieve a sufficiently dramatic 426 
improvement in potency against the target, the impact of a type II target protection mechanism could 427 
effectively be negated by reducing the level of reduced susceptibility it mediates below the threshold 428 
for true clinical resistance. 429 
 430 
In principle, it should also be feasible to generate small-molecule inhibitors of the different types of 431 
target protection mechanisms. In this regard, a recent study used fragment-based screening to identify 432 
an inhibitor of OptrA that competes with ATP for binding, and which thereby effects a 30% reduction 433 
in the essential ATPase activity of the enzyme96. In practice, the potential therapeutic utility of 434 
inhibiting a specific target protection protein will need to be carefully assessed on a case-by-case basis; 435 
only for an antibacterial drug for which the target protection mechanism in question is the major —436 
preferably the sole — source of resistance encountered clinically will it likely prove worthwhile to 437 
generate a specific target protection inhibitor with a view to rejuvenating antibacterial activity. 438 
 439 
[H1] Concluding remarks 440 
Target protection can no longer be considered a rare or unusual antibiotic-resistance mechanism of 441 
limited clinical importance; it is in fact one of the predominant mechanisms by which bacterial 442 
pathogens resist a host of drug classes that include the fluoroquinolones and the overwhelming 443 
majority of protein synthesis inhibitors in clinical use. 444 
 445 
Target protection does not proceed via a single, uniform mechanism, and three mechanistic types of 446 
target protection have now been defined (Fig. 1): direct antibiotic displacement (type I); allosteric 447 
antibiotic removal (type II); and restoration of target function to overcome antibiotic-mediated 448 
inhibition (type III). Despite detailed structural and functional analysis of target protection systems in 449 
recent years, and as discussed above, gaps in our understanding remain. Some of these gaps may prove 450 
challenging to fill given the inherent difficulty of dissecting the complex interplay between a resistance 451 
protein, an antibiotic target and an antibiotic molecule. Nevertheless, a more comprehensive 452 
understanding of target protection will be vital both to raise our fundamental knowledge to a level 453 
comparable to that already gained for other mechanistic classes of resistance, and to assist efforts 454 
already underway to devise approaches for overcoming target protection-mediated antibiotic 455 
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  484 
Figure 1. Overview of target protection  types. Target protection proteins (TPPS) can mediate 485 
antibiotic resistance by (a) sterically removing the drug from the target (type I), (b) by inducing 486 
conformational changes within the target that allosterically dissociate the drug from the target (type 487 
II), or (c) by inducing conformational changes within the target that restore functionality despite the 488 
presence of the bound antibiotic (type III). 489 
 490 
Figure 2. Protection of ribosomes from tetracyline by Tet(M). (a) Model for Tet(M)-mediated 491 
tetracycline (Tet) resistance via ribosome binding and release of tetracycline (Tet). (b) Structure of 492 
Tet(M) on the 70S ribosome24. (c-d) Relative binding position of loop III of domain IV of Tet(M) relative 493 
to tetracycline (c) and tigecycline (d) 10,24. Part a modified from Ref.22.  494 
 495 
Figure 3. Ribosomal protection against antibiotics mediated by the ARE ABC-F proteins. (a) Model for 496 
ARE ABC-F-type antibiotic resistance, using VmlR as example. (b) Overview of VmlR and P/V-tRNA on 497 
the ribosome with transverse section of the 50S subunit revealing the nascent polypeptide exit tunnel. 498 
(c) (b) VmlR superimposed with the group A streptogramin A, virginiamycin M (VgM, PDB ID 1YIT)97, 499 
the lincomycin (Lnc, PDB ID 5HKV) and the pleuromutilin, tiamulin (Tia, PDB ID 1XBP). (d) Comparison 500 
of the binding-site of MsrE (PDB ID 5ZLU), the group B streptogramin virginiamycin S (VgS, PDB ID 501 
1YIT)97 and the macrolide, erythromycin (Ery, PDB ID 4V7U)98. 502 
 503 
Figure 4. Target protection mediated by FusB-type proteins. (a) FusB-type fusidic acid (Fus) resistance 504 
results from the ability of the resistance protein to bind elongation factor G EF-G and drive its 505 
dissociation from the ribosome even in the presence of fusidic acid. Although not central to the 506 
protection mechanism, fusidic acid probably dissociates from EF-G once the elongation factor has left 507 
the ribosome, as it has only low affinity for free EF-G. (b) Structure of EF-G stalled by fusidic acid on the 508 
70S ribosome63. (c) Model for the interaction of FusB with domain IV of EF-G (blue). Part c modified 509 
fromRef 62.  510 
 511 
Figure 5. Proposed mechanism of target protection by HflXr proteins. (a) Overview of HflX on the 50S 512 
subunit with transverse section revealing the nascent polypeptide exit tunnel (NPETZoom of the loop 513 
within the N-terminal domain of HflX superimposed with lincomycin (Lnc, , PDB ID 5HKV, left panel)99 514 
and erythromycin (Ery, PDB ID 4V7U, left panel)98, and with virginiamycin M (VgM, PDB ID 1YIT, right 515 
panel)97, tiamulin (Tia, PDB ID 1XBP, right panel)100, linezolid (Lnz, PDB ID 3DLL, right panel)101 and 516 
virginiamycin S (VgS, PDB ID 1YIT, right panel)97. (b) Sequence alignment of the resistance-associated 517 
loop region within the N-terminal domain of selected HflX and HflXr representatives, showing 518 
independently evolved insertions in HflXr and HflX.  519 
 520 
Figure 6. The evolution of target protections proteins within the elongation factor 2 and ABC-F 521 
families of translation factors. (a) Tetracycline ribosomal protection proteins (TRPP), translation 522 
elongation factor-G (EF-G), eukaryotic elongation factor 2 (eEF2) and archaeal EF2 (aEF2) sequences 523 
were selected from the translational GTPase database from Ref. 102. (b) The ABC-F sequences and 524 
classifications are taken from a previous analysis32. The bacterial branches (in black) are members of 525 
multiple subfamilies, some of which may be uncharacterised resistance factors, but some are almost 526 
certainly specialised translation factors such as the indicated EttA clade33,34. The eukaryotic group (in 527 
green) contains three known translation factors (ABC50/ABCF1103, Arb1/ABCF2104 and 528 
Gcn20/ABCF3105). Trees shown are maximum likelihood protein phylogenies generated using RaxML106, 529 
using the LG model, 100 bootstrap replicates and alignments trimmed to remove columns with >50% 530 
gap characters. Archaeal and eukaryotic proteins are shown with green and purple respectively; all 531 
other sequences are bacterial, with clades containing known TRPPs highlighted in red. 532 
  533 
References  534 
1 O'Neill, J. Tackling drug-resistant infections globally: Final report and recommendations. 535 
https://amr-review.org/Publications.html (2016). 536 
2 Abraham, E. P. & Chain, E. An Enzyme from Bacteria able to Destroy Penicillin. Nature 146, 537 
837 (1940). 538 
3 Blair, J. M., Webber, M. A., Baylay, A. J., Ogbolu, D. O. & Piddock, L. J. Molecular mechanisms 539 
of antibiotic resistance. Nat Rev Microbiol 13, 42-51, doi:10.1038/nrmicro3380 (2015). 540 
4 Sharkey, L. K. & O’Neill, A. J. in Bacterial Resistance to Antibiotics: From Molecules to Man 541 
(Wiley & Sons, 2019). 542 
5 Manavathu, E. K., Fernandez, C. L., Cooperman, B. S. & Taylor, D. E. Molecular studies on the 543 
mechanism of tetracycline resistance mediated by Tet(O). Antimicrob Agents Chemother 34, 71-77, 544 
doi:10.1128/aac.34.1.71 (1990). 545 
6 Burdett, V. Purification and characterization of Tet(M), a protein that renders ribosomes 546 
resistant to tetracycline. J Biol Chem 266, 2872-2877 (1991). 547 
7 Nguyen, F. et al. Tetracycline antibiotics and resistance mechanisms. Biol Chem 395, 559-575 548 
(2014). 549 
8 Brodersen, D. E. et al. The structural basis for the action of the antibiotics tetracycline, 550 
pactamycin, and hygromycin B on the 30S ribosomal subunit. Cell 103, 1143-1154 (2000). 551 
9 Pioletti, M. et al. Crystal structures of complexes of the small ribosomal subunit with 552 
tetracycline, edeine and IF3. EMBO J. 20, 1829-1839 (2001). 553 
10 Jenner, L. et al. Structural basis for potent inhibitory activity of the antibiotic tigecycline 554 
during protein synthesis. Proc Natl Acad Sci U S A 110, 3812-3816 (2013). 555 
11 Schedlbauer, A. et al. Structural characterization of an alternative mode of tigecycline binding 556 
to the bacterial ribosome. Antimicrob Agents Chemother 59, 2849-2854, doi:10.1128/AAC.04895-14 557 
(2015). 558 
12 https://faculty.washington.edu/marilynr/tetweb1.pdf.  559 
13 Connell, S. R., Tracz, D. M., Nierhaus, K. H. & Taylor, D. E. Ribosomal protection proteins and 560 
their mechanism of tetracycline resistance. Antimicrob Agents Chemother 47, 3675-3681. (2003). 561 
14 Roberts, M. C. Update on acquired tetracycline resistance genes. FEMS Microbiol Lett 245, 562 
195-203, doi:10.1016/j.femsle.2005.02.034 (2005). 563 
15 Shen, Y. et al. Identification and Characterization of Fluoroquinolone Non-susceptible 564 
Streptococcus pyogenes Clones Harboring Tetracycline and Macrolide Resistance in Shanghai, China. 565 
Front Microbiol 9, 542, doi:10.3389/fmicb.2018.00542 (2018). 566 
16 Metcalf, B. J. et al. Using whole genome sequencing to identify resistance determinants and 567 
predict antimicrobial resistance phenotypes for year 2015 invasive pneumococcal disease isolates 568 
recovered in the United States. Clin Microbiol Infect 22, 1002 e1001-1002 e1008, 569 
doi:10.1016/j.cmi.2016.08.001 (2016). 570 
17 Trzcinski, K., Cooper, B. S., Hryniewicz, W. & Dowson, C. G. Expression of resistance to 571 
tetracyclines in strains of methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 45, 572 
763-770 (2000). 573 
18 Emaneini, M. et al. Distribution of genes encoding tetracycline resistance and aminoglycoside 574 
modifying enzymes in Staphylococcus aureus strains isolated from a burn center. Ann Burns Fire 575 
Disasters 26, 76-80 (2013). 576 
19 Nishimoto, Y. et al. Analysis of the prevalence of tetracycline resistance genes in clinical 577 
isolates of Enterococcus faecalis and Enterococcus faecium in a Japanese hospital. Microb Drug Resist 578 
11, 146-153, doi:10.1089/mdr.2005.11.146 (2005). 579 
20 Tian, Y., Yu, H. & Wang, Z. Distribution of acquired antibiotic resistance genes among 580 
Enterococcus spp. isolated from a hospital in Baotou, China. BMC Res Notes 12, 27, 581 
doi:10.1186/s13104-019-4064-z (2019). 582 
21 Spahn, C. M. et al. Localization of the ribosomal protection protein Tet(O) on the ribosome 583 
and the mechanism of tetracycline resistance. Mol Cell 7, 1037-1045 (2001). 584 
22 Dönhöfer, A. et al. Structural basis for TetM-mediated tetracycline resistance. Proc Natl Acad 585 
Sci U S A 109, 16900-16905 (2012). 586 
23 Li, W. et al. Mechanism of tetracycline resistance by ribosomal protection protein Tet(O). Nat 587 
Commun 4, 1477 (2013). 588 
24 Arenz, S., Nguyen, F., Beckmann, R. & Wilson, D. N. Cryo-EM structure of the tetracycline 589 
resistance protein TetM in complex with a translating ribosome at 3.9-A resolution. Proc Natl Acad Sci 590 
U S A 112, 5401-5406, doi:10.1073/pnas.1501775112 (2015). 591 
This study presents the highest resolution cryo-electron microscopy structure of TetM in complex 592 
with the ribosome, revealing that these TRPPs mediate target protection directly (type I) rather than 593 
indirectly (type II).25 Burdett, V. Tet(M)-promoted release of tetracycline from ribosomes is GTP 594 
dependent. J Bacteriol 178, 3246-3251 (1996). 595 
26 Trieber, C. A., Burkhardt, N., Nierhaus, K. H. & Taylor, D. E. Ribosomal Protection from 596 
Tetracycline Mediated by Tet(O) Interaction with Ribosomes Is GTP-Dependent. Biol Chem 379, 847-597 
855 (1998). 598 
27 Grossman, T. H. et al. Target- and resistance-based mechanistic studies with TP-434, a novel 599 
fluorocycline antibiotic. Antimicrob Agents Chemother 56, 2559-2564, doi:10.1128/AAC.06187-11 600 
(2012). 601 
28 Draper, M. P. et al. Mechanism of action of the novel aminomethylcycline antibiotic 602 
omadacycline. Antimicrob Agents Chemother 58, 1279-1283, doi:10.1128/AAC.01066-13 (2014). 603 
29 Linkevicius, M., Sandegren, L. & Andersson, D. I. Potential of Tetracycline Resistance Proteins 604 
To Evolve Tigecycline Resistance. Antimicrob Agents Chemother 60, 789-796, 605 
doi:10.1128/AAC.02465-15 (2016). 606 
30 Sharkey, L. K., Edwards, T. A. & O'Neill, A. J. ABC-F Proteins Mediate Antibiotic Resistance 607 
through Ribosomal Protection. MBio 7, e01975, doi:10.1128/mBio.01975-15 (2016). 608 
This study provided the first direct evidence that ARE ABC-F proteins mediate antibiotic resistance 609 
using target protection rather than efflux. 610 
31 Sharkey, L. K. R. & O'Neill, A. J. Antibiotic Resistance ABC-F Proteins: Bringing Target 611 
Protection into the Limelight. ACS Infect Dis 4, 239-246, doi:10.1021/acsinfecdis.7b00251 (2018). 612 
32 Murina, V. et al. ABCF ATPases Involved in Protein Synthesis, Ribosome Assembly and 613 
Antibiotic Resistance: Structural and Functional Diversification across the Tree of Life. J. Mol. Biol., 614 
doi:10.1016/j.jmb.2018.12.013 (2018). 615 
33 Boel, G. et al. The ABC-F protein EttA gates ribosome entry into the translation elongation 616 
cycle. Nat Struct Mol Biol 21, 143-151, doi:10.1038/nsmb.2740 (2014). 617 
34 Chen, B. et al. EttA regulates translation by binding the ribosomal E site and restricting 618 
ribosome-tRNA dynamics. Nat Struct Mol Biol 21, 152-159, doi:10.1038/nsmb.2741 (2014). 619 
35 Crowe-McAuliffe, C. et al. Structural basis for antibiotic resistance mediated by the Bacillus 620 
subtilis ABCF ATPase VmlR. Proc Natl Acad Sci U S A 115, 8978-8983, doi:10.1073/pnas.1808535115 621 
(2018). 622 
36 Wang, Y. et al. A novel gene, optrA, that confers transferable resistance to oxazolidinones and 623 
phenicols and its presence in Enterococcus faecalis and Enterococcus faecium of human and animal 624 
origin. J Antimicrob Chemother 70, 2182-2190, doi:10.1093/jac/dkv116 (2015). 625 
37 Murina, V., Kasari, M., Hauryliuk, V. & Atkinson, G. C. Antibiotic resistance ABCF proteins reset 626 
the peptidyl transferase centre of the ribosome to counter translational arrest. Nucleic Acids Res. 46, 627 
3753-3763, doi:10.1093/nar/gky050 (2018). 628 
38 Antonelli, A. et al. Characterization of poxtA, a novel phenicol-oxazolidinone-tetracycline 629 
resistance gene from an MRSA of clinical origin. J Antimicrob Chemother 73, 1763-1769, 630 
doi:10.1093/jac/dky088 (2018). 631 
39 Su, W. et al. Ribosome protection by antibiotic resistance ATP-binding cassette protein. Proc 632 
Natl Acad Sci U S A 115, 5157-5162, doi:10.1073/pnas.1803313115 (2018).Together with reference 35, 633 
this study offered the first structural insights into how ARE ABC-F proteins interact with the ribosome 634 
to mediate target protection indirectly (type II) 635 
40 Ero, R., Kumar, V., Su, W. & Gao, Y. G. Ribosome protection by ABC-F proteins-Molecular 636 
mechanism and potential drug design. Protein Sci. 28, 684-693, doi:doi: 10.1002/pro.3589 (2019). 637 
41 Novotna, G. & Janata, J. A new evolutionary variant of the streptogramin A resistance protein, 638 
Vga(A)LC, from Staphylococcus haemolyticus with shifted substrate specificity towards lincosamides. 639 
Antimicrob Agents Chemother 50, 4070-4076, doi:10.1128/AAC.00799-06 (2006). 640 
42 Lenart, J., Vimberg, V., Vesela, L., Janata, J. & Balikova Novotna, G. Detailed mutational 641 
analysis of Vga(A) interdomain linker: implication for antibiotic resistance specificity and mechanism. 642 
Antimicrob Agents Chemother 59, 1360-1364, doi:10.1128/AAC.04468-14 (2015). 643 
43 Ohki, R., Tateno, K., Takizawa, T., Aiso, T. & Murata, M. Transcriptional termination control of 644 
a novel ABC transporter gene involved in antibiotic resistance in Bacillus subtilis. J Bacteriol 187, 645 
5946-5954, doi:10.1128/JB.187.17.5946-5954.2005 (2005). 646 
44 Wilson, D. N. The ABC of Ribosome-Related Antibiotic Resistance. MBio 7, 647 
doi:10.1128/mBio.00598-16 (2016). 648 
45 Orelle, C. et al. Tools for characterizing bacterial protein synthesis inhibitors. Antimicrob 649 
Agents Chemother 57, 5994-6004, doi:10.1128/AAC.01673-13 (2013). 650 
46 Nakahigashi, K. et al. Comprehensive identification of translation start sites by tetracycline-651 
inhibited ribosome profiling. DNA Res 23, 193-201, doi:10.1093/dnares/dsw008 (2016). 652 
47 Dar, D. et al. Term-seq reveals abundant ribo-regulation of antibiotics resistance in bacteria. 653 
Science 352, aad9822, doi:10.1126/science.aad9822 (2016). 654 
48 Chotewutmontri, P. & Barkan, A. Multilevel effects of light on ribosome dynamics in 655 
chloroplasts program genome-wide and psbA-specific changes in translation. PLoS Genet 14, 656 
e1007555, doi:10.1371/journal.pgen.1007555 (2018). 657 
49 Wilson, D. N. Ribosome-targeting antibiotics and mechanisms of bacterial resistance. Nat Rev 658 
Microbiol 12, 35-48, doi:10.1038/nrmicro3155 (2014). 659 
50 Marks, J. et al. Context-specific inhibition of translation by ribosomal antibiotics targeting the 660 
peptidyl transferase center. Proc Natl Acad Sci U S A 113, 12150-12155, 661 
doi:10.1073/pnas.1613055113 (2016). 662 
51 Seo, H. S. et al. EF-G-dependent GTPase on the ribosome, conformational change and fusidic 663 
acid inhibition. Biochemistry 45, 2504-2514, doi:10.1021/bi0516677 (2006). 664 
52 Tanaka, N., Kinoshita, T. & Masukawa, H. Mechanism of protein synthesis inhibition by fusidic 665 
acid and related antibiotics. Biochem Biophys Res Comm 30, 278-283. (1968). 666 
53 Bodley, J. W., Zieve, F. J., Lin, L. & Zieve, S. T. Formation of the ribosome-G factor-GDP 667 
complex in the presence of fusidic acid. Biochem Biophys Res Comm 37, 437-443. (1969). 668 
54 McLaws, F. B., Larsen, A. R., Skov, R. L., Chopra, I. & O'Neill, A. J. Distribution of fusidic acid 669 
resistance determinants in methicillin-resistant Staphylococcus aureus. Antimicrobial Agents 670 
Chemother 55, 1173-1176, doi:10.1128/AAC.00817-10 (2011). 671 
55 McLaws, F., Chopra, I. & O'Neill, A. J. High prevalence of resistance to fusidic acid in clinical 672 
isolates of Staphylococcus epidermidis. J Antimicrob Chemother 61, 1040-1043. Epub 2008 Feb 1025. 673 
(2008). 674 
56 O'Neill, A. J., Larsen, A. R., Henriksen, A. S. & Chopra, I. A fusidic acid-resistant epidemic strain 675 
of Staphylococcus aureus carries the fusB determinant, whereas fusA mutations are prevalent in 676 
other resistant isolates. Antimicrob Agents Chemother 48, 3594-3597 (2004). 677 
57 Castanheira, M., Watters, A. A., Bell, J. M., Turnidge, J. D. & Jones, R. N. Fusidic acid resistance 678 
rates and prevalence of resistance mechanisms among Staphylococcus spp. isolated in North America 679 
and Australia, 2007-2008. Antimicrob Agents Chemother 54, 3614-3617, doi:10.1128/AAC.01390-09 680 
(2010). 681 
58 Castanheira, M., Watters, A. A., Mendes, R. E., Farrell, D. J. & Jones, R. N. Occurrence and 682 
molecular characterization of fusidic acid resistance mechanisms among Staphylococcus spp. from 683 
European countries (2008). J Antimicrob Chemother 65, 1353-1358, doi:10.1093/jac/dkq094 (2010). 684 
59 O'Neill, A. J. & Chopra, I. Molecular basis of fusB-mediated resistance to fusidic acid in 685 
Staphylococcus aureus. Mol Microbiol 59, 664-676, doi:10.1111/j.1365-2958.2005.04971.x (2006). 686 
60 Cox, G. et al. Ribosome clearance by FusB-type proteins mediates resistance to the antibiotic 687 
fusidic acid. Proc Natl Acad Sci U S A 109, 2102-2107, doi:10.1073/pnas.1117275109 (2012). 688 
61 Guo, X. et al. Structure and function of FusB: an elongation factor G-binding fusidic acid 689 
resistance protein active in ribosomal translocation and recycling. Open Biol 2, 120016, 690 
doi:10.1098/rsob.120016 (2012). 691 
62 Tomlinson, J. H., Thompson, G. S., Kalverda, A. P., Zhuravleva, A. & O'Neill, A. J. A target-692 
protection mechanism of antibiotic resistance at atomic resolution: insights into FusB-type fusidic 693 
acid resistance. Sci Rep 6, 19524, doi:10.1038/srep19524 (2016). 694 
This study provides the most recent model for how FusB-type proteins promote dissociation of EF-G 695 
from the ribosome even in the presence of the antibiotic fusidic acid, thereby mediating type III target 696 
protection. 697 
63 Gao, Y. G. et al. The structure of the ribosome with elongation factor G trapped in the 698 
posttranslocational state. Science 326, 694-699, doi:10.1126/science.1179709 (2009). 699 
64 Li, W., Trabuco, L. G., Schulten, K. & Frank, J. Molecular dynamics of EF-G during translocation. 700 
Proteins 79, 1478-1486, doi:10.1002/prot.22976 (2011). 701 
65 Zhou, J., Lancaster, L., Donohue, J. P. & Noller, H. F. Crystal structures of EF-G-ribosome 702 
complexes trapped in intermediate states of translocation. Science 340, 1236086, 703 
doi:10.1126/science.1236086 (2013). 704 
66 Tran, J. H. & Jacoby, G. A. Mechanism of plasmid-mediated quinolone resistance. Proc Natl 705 
Acad Sci U S A 99, 5638-5642, doi:10.1073/pnas.082092899 (2002). 706 
This study provided the first detailed decription of Qnr-mediated resistance to quinolones. 707 
67 Tran, J. H., Jacoby, G. A. & Hooper, D. C. Interaction of the plasmid-encoded quinolone 708 
resistance protein Qnr with Escherichia coli DNA gyrase. Antimicrob Agents Chemother 49, 118-125. 709 
(2005). 710 
68 Tran, J. H., Jacoby, G. A. & Hooper, D. C. Interaction of the plasmid-encoded quinolone 711 
resistance protein QnrA with Escherichia coli topoisomerase IV. Antimicrob Agents Chemother 49, 712 
3050-3052, doi:10.1128/AAC.49.7.3050-3052.2005 (2005). 713 
69 Jacoby, G. A., Strahilevitz, J. & Hooper, D. C. Plasmid-mediated quinolone resistance. Microbiol 714 
Spectr 2, doi:10.1128/microbiolspec.PLAS-0006-2013 (2014). 715 
70 Vetting, M. W. et al. Structure of QnrB1, a plasmid-mediated fluoroquinolone resistance 716 
factor. J Biol Chem 286, 25265-25273, doi:10.1074/jbc.M111.226936 (2011). 717 
71 Xiong, X., Bromley, E. H., Oelschlaeger, P., Woolfson, D. N. & Spencer, J. Structural insights 718 
into quinolone antibiotic resistance mediated by pentapeptide repeat proteins: conserved surface 719 
loops direct the activity of a Qnr protein from a gram-negative bacterium. Nucleic Acids Res. 39, 720 
3917-3927, doi:10.1093/nar/gkq1296 (2011). 721 
72 Tenson, T. & Mankin, A. S. Short peptides conferring resistance to macrolide antibiotics. 722 
Peptides 22, 1661-1668, doi:10.1016/s0196-9781(01)00501-0 (2001). 723 
73 Tripathi, S., Kloss, P. S. & Mankin, A. S. Ketolide resistance conferred by short peptides. J Biol 724 
Chem 273, 20073-20077, doi:10.1074/jbc.273.32.20073 (1998). 725 
74 Lovmar, M. et al. The molecular mechanism of peptide-mediated erythromycin resistance. J 726 
Biol Chem 281, 6742-6750, doi:10.1074/jbc.M511918200 (2006). 727 
75 Tenson, T., Xiong, L., Kloss, P. & Mankin, A. S. Erythromycin resistance peptides selected from 728 
random peptide libraries. J Biol Chem 272, 17425-17430, doi:10.1074/jbc.272.28.17425 (1997). 729 
76 Vimberg, V., Xiong, L., Bailey, M., Tenson, T. & Mankin, A. Peptide-mediated macrolide 730 
resistance reveals possible specific interactions in the nascent peptide exit tunnel. Mol Microbiol 54, 731 
376-385, doi:10.1111/j.1365-2958.2004.04290.x (2004). 732 
77 Tenson, T., DeBlasio, A. & Mankin, A. A functional peptide encoded in the Escherichia coli 23S 733 
rRNA. Proc Natl Acad Sci U S A 93, 5641-5646, doi:10.1073/pnas.93.11.5641 (1996). 734 
78 Lau, C. H., van Engelen, K., Gordon, S., Renaud, J. & Topp, E. Novel Antibiotic Resistance 735 
Determinants from Agricultural Soil Exposed to Antibiotics Widely Used in Human Medicine and 736 
Animal Farming. Appl Environ Microbiol 83, doi:10.1128/AEM.00989-17 (2017). 737 
79 Duval, M. et al. HflXr, a homolog of a ribosome-splitting factor, mediates antibiotic resistance. 738 
Proc Natl Acad Sci U S A 115, 13359-13364, doi:10.1073/pnas.1810555115 (2018). 739 
This study suggests that some bacteria contain HflX homologues capable of mediating target protection 740 
against lincomycins and macrolide antibiotics. 741 
80 Zhang, Y. et al. HflX is a ribosome-splitting factor rescuing stalled ribosomes under stress 742 
conditions. Nat Struct Mol Biol 22, 906-913, doi:10.1038/nsmb.3103 (2015). 743 
81 Srinivasan, K., Dey, S. & Sengupta, J. Structural modules of the stress-induced protein HflX: an 744 
outlook on its evolution and biological role. Curr Genet 65, 363-370, doi:10.1007/s00294-018-0905-x 745 
(2019). 746 
82 Rudra, P., Hurst-Hess, K. R., Cotten, K. L., Partida-Miranda, A. & Ghosh, P. Mycobacterial HflX 747 
is a ribosome splitting factor that mediates antibiotic resistance. Proc Natl Acad Sci U S A 117, 629-748 
634, doi:10.1073/pnas.1906748117 (2020). 749 
83 Kobras, C. M. et al. BceAB-Type Antibiotic Resistance Transporters Appear To Act by Target 750 
Protection of Cell Wall Synthesis. Antimicrob Agents Chemother 64, doi:10.1128/AAC.02241-19 751 
(2020). 752 
This study suggests that BceAB-type proteins mediate resistance to bacitracin by a target protection 753 
mechanism outside of the bacterial cell. 754 
84 Clemens, R., Zaschke-Kriesche, J., Khosa, S. & Smits, S. H. J. Insight into Two ABC Transporter 755 
Families Involved in Lantibiotic Resistance. Front Mol Biosci 4, 91, doi:10.3389/fmolb.2017.00091 756 
(2017). 757 
85 Popella, P. et al. VraH Is the Third Component of the Staphylococcus aureus VraDEH System 758 
Involved in Gallidermin and Daptomycin Resistance and Pathogenicity. Antimicrob Agents Chemother 759 
60, 2391-2401, doi:10.1128/AAC.02865-15 (2016). 760 
86 Blake, K. L., Randall, C. P. & O'Neill, A. J. In vitro studies indicate a high resistance potential for 761 
the lantibiotic nisin in Staphylococcus aureus and define a genetic basis for nisin resistance. 762 
Antimicrob Agents Chemother 55, 2362-2368, doi:AAC.01077-10 [pii] 763 
10.1128/AAC.01077-10 (2011). 764 
87 Randall, C. P. et al. Acquired Nisin Resistance in Staphylococcus aureus Involves Constitutive 765 
Activation of an Intrinsic Peptide Antibiotic Detoxification Module. mSphere 3, 766 
doi:10.1128/mSphereDirect.00633-18 (2018). 767 
88 Gebhard, S. ABC transporters of antimicrobial peptides in Firmicutes bacteria - phylogeny, 768 
function and regulation. Mol Microbiol 86, 1295-1317, doi:10.1111/mmi.12078 (2012). 769 
89 Singh, K. V., Weinstock, G. M. & Murray, B. E. An Enterococcus faecalis ABC homologue (Lsa) is 770 
required for the resistance of this species to clindamycin and quinupristin-dalfopristin. Antimicrob 771 
Agents Chemother 46, 1845-1850, doi:10.1128/aac.46.6.1845-1850.2002 (2002). 772 
90 Karray, F. et al. Organization of the biosynthetic gene cluster for the macrolide antibiotic 773 
spiramycin in Streptomyces ambofaciens. Microbiology 153, 4111-4122, 774 
doi:10.1099/mic.0.2007/009746-0 (2007). 775 
91 Gonzalez-Plaza, J. J. et al. Functional Repertoire of Antibiotic Resistance Genes in Antibiotic 776 
Manufacturing Effluents and Receiving Freshwater Sediments. Front Microbiol 8, 2675, 777 
doi:10.3389/fmicb.2017.02675 (2017). 778 
92 Atkinson, G. C. et al. Distinction between the Cfr methyltransferase conferring antibiotic 779 
resistance and the housekeeping RlmN methyltransferase. Antimicrob Agents Chemother 57, 4019-780 
4026, doi:10.1128/AAC.00448-13 (2013). 781 
93 Kaminska, K. H. et al. Insights into the structure, function and evolution of the radical-SAM 782 
23S rRNA methyltransferase Cfr that confers antibiotic resistance in bacteria. Nucleic Acids Res. 38, 783 
1652-1663, doi:10.1093/nar/gkp1142 (2010). 784 
94 Park, A. K., Kim, H. & Jin, H. J. Phylogenetic analysis of rRNA methyltransferases, Erm and 785 
KsgA, as related to antibiotic resistance. FEMS Microbiol Lett 309, 151-162, doi:10.1111/j.1574-786 
6968.2010.02031.x (2010). 787 
95 Shaw, K. J. et al. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, 788 
against linezolid-resistant strains. Antimicrob Agents Chemother 52, 4442-4447, 789 
doi:10.1128/AAC.00859-08 (2008). 790 
96 Zhong, X. et al. A novel inhibitor of the new antibiotic resistance protein OptrA. Chem Biol 791 
Drug Des 92, 1458-1467, doi:10.1111/cbdd.13311 (2018). 792 
97 Tu, D., Blaha, G., Moore, P. B. & Steitz, T. A. Structures of MLSBK antibiotics bound to mutated 793 
large ribosomal subunits provide a structural explanation for resistance. Cell 121, 257-270, 794 
doi:10.1016/j.cell.2005.02.005 (2005). 795 
98 Dunkle, J. A., Xiong, L., Mankin, A. S. & Cate, J. H. Structures of the Escherichia coli ribosome 796 
with antibiotics bound near the peptidyl transferase center explain spectra of drug action. Proc Natl 797 
Acad Sci U S A 107, 17152-17157, doi:10.1073/pnas.1007988107 (2010). 798 
99 Matzov, D. et al. Structural insights of lincosamides targeting the ribosome of Staphylococcus 799 
aureus. Nucleic Acids Res. 45, 10284-10292, doi:10.1093/nar/gkx658 (2017). 800 
100 Schlunzen, F., Pyetan, E., Fucini, P., Yonath, A. & Harms, J. M. Inhibition of peptide bond 801 
formation by pleuromutilins: the structure of the 50S ribosomal subunit from Deinococcus 802 
radiodurans in complex with tiamulin. Mol Microbiol 54, 1287-1294, doi:10.1111/j.1365-803 
2958.2004.04346.x (2004). 804 
101 Wilson, D. N. et al. The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase 805 
center and effect tRNA positioning. Proc Natl Acad Sci U S A 105, 13339-13344, 806 
doi:10.1073/pnas.0804276105 (2008). 807 
102 Atkinson, G. C. The evolutionary and functional diversity of classical and lesser-known 808 
cytoplasmic and organellar translational GTPases across the tree of life. BMC Genomics 16, 78, 809 
doi:10.1186/s12864-015-1289-7 (2015). 810 
103 Stewart, J. D., Cowan, J. L., Perry, L. S., Coldwell, M. J. & Proud, C. G. ABC50 mutants modify 811 
translation start codon selection. Biochem J 467, 217-229, doi:10.1042/BJ20141453 (2015). 812 
104 Su, T. et al. Structure and function of Vms1 and Arb1 in RQC and mitochondrial proteome 813 
homeostasis. Nature 570, 538-542, doi:10.1038/s41586-019-1307-z (2019). 814 
105 Vazquez de Aldana, C. R., Marton, M. J. & Hinnebusch, A. G. GCN20, a novel ATP binding 815 
cassette protein, and GCN1 reside in a complex that mediates activation of the eIF-2 alpha kinase 816 
GCN2 in amino acid-starved cells. EMBO J 14, 3184-3199 (1995). 817 
106 Stamatakis, A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large 818 
phylogenies. Bioinformatics 30, 1312-1313, doi:10.1093/bioinformatics/btu033 (2014). 819 
 820 
  821 
 
Figure 1. Overview of target protection (TP) Types I-III. Target protection proteins can 
mediate antibiotic resistance by (a) sterically removing the drug from the target (Type I TP), 
(b) inducing conformational changes within the target that allosterically dissociate the drug 
from the target (Type II TP), or (c) inducing conformational changes within the target that 




Figure 2. Protection of ribosomes from tetracyline by Tet(M). (a) Model for Tet(M)-mediated 
tetracycline resistance via ribosome binding and release of tetracycline (Tet) (modified from 
Dönhöfer et al.22). (b) Structure of Tet(M) on the 70S ribosome24. (c-d) Relative binding 




Figure 3. Ribosomal protection against antibiotics mediated by the ARE ABC-F proteins. (a) 
Model for ARE ABC-F-type antibiotic resistance (a). (b) Overview of VmlR (orange) and P/V-
tRNA (green) on the ribosome (30S shown in yellow, 50S in grey) with transverse section of 
the 50S subunit revealing the nascent polypeptide exit tunnel33. (c) Zoom of (b) with VmlR 
(orange) superimposed with the STGA, virginiamycin M (VgM, green, PDB ID 1YIT)94, the LIN, 
lincomycin (Lnc, salmon, PDB ID 5HKV) and the PLM, tiamulin (Tia, purple, PDB ID 1XBP). (d) 
same view as (c) but comparing the binding site of MsrE (blue, PDB ID 5ZLU), the STGB 





Figure 4. Target protection mediated by FusB-type proteins. (a) FusB-type fusidic acid (FA) 
resistance results from the ability of the resistance protein to bind EF-G and drive its 
dissociation from the ribosome even in the presence of FA. Although not central to the 
protection mechanism, FA likely dissociates from EF-G once the latter has left the ribosome, 
since it has only low affinity for free EF-G. (b) Structure of EF-G stalled by fusidic acid on the 
70S ribosome57. (c) Model for the interaction of FusB (teal) with domain IV of EF-G (blue) 






















Figure 5. Proposed mechanism of target protection by HflXr proteins. (a) Overview of HflX 
(purple) on the 50S subunit (grey) with transverse section revealing the nascent polypeptide 
exit tunnel (NPET). Zoom of the loop (orange) within the N-terminal domain of HflX (purple) 
superimposed with (left) lincomycin (Lnc, salmon, PDB ID 5HKV)96 and erythromycin (Ery, tan, 
PDB ID 4V7U)95, and (right) with virginiamycin M (VgM, green, PDB ID 1YIT)94, tiamulin (Tia, 
purple, PDB ID 1XBP)97, linezolid (Lnz, blue, PDB ID 3DLL)98 and virginiamycin S (VgS, white, 
PDB ID 1YIT)94. (b) Sequence alignment of the resistance-associated loop region (shaded) 
within the N-terminal domain of selected HflX and HflXr representatives, showing 





Figure 6. The evolution of TP proteins within the EF2 and ABC-F families of translation 
factors. (a) TRPP, EF-G, eEF2 and aEF2 sequences were selected from our translational GTPase 
database99. (b) The ABC-F sequences and classifications are from our previous analysis32. The 
bacterial branches (in black) are members of multiple subfamilies, some of which may be 
uncharacterised resistance factors, but some are almost certainly specialised translation 
factors such as the indicated EttA clade85,86. The eukaryotic group (in green) contains three 
known translation factors (ABC50/ABCF1100, Arb1/ABCF2101 and Gcn20/ABCF3102). Trees 
shown are maximum likelihood protein phylogenies made with RaxML103, using the LG model, 
100 bootstrap replicates and alignments trimmed to remove columns with >50% gap 
characters. Archaeal and eukaryotic proteins are shown with green and purple highlighting 
respectively; all other sequences are bacterial, with clades containing known TRPPs 


























Bootstrap support for labeled 
groups and their closest 
associations, where support 
is significant: 
